Navigation Links
Mylan Announces Exclusive Distribution Partnership with Humeca to Expand Burn and Wound Care Portfolio
Date:3/22/2011

PITTSBURGH, March 22, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary UDL Laboratories, part of the Mylan Institutional business, has entered a license agreement with Humeca, a leading plastic surgery and burn treatment products company, for the exclusive U.S. distribution rights of Humeca products. Humeca, which is based in the Netherlands, has a portfolio that includes products used by burn, plastic and reconstructive surgeons to repair skin defects.

Mylan Institutional President Matt Erick commented: "Mylan Institutional is extremely pleased to have found a partner as strong as Humeca to accelerate our growth in the burn and wound care space. For the first time in the U.S., plastic and reconstructive surgeons will have access to Humeca's modified MEEK micrografting system, the method of choice for skin transplantation. The addition of Humeca's innovative products to UDL's established line of advanced wound and burn care products positions Mylan Institutional for growth in this sector."

Humeca's modified MEEK micrografting system greatly reduces the donor surface area required for skin transplantation when compared to the commonly-used mesh graft technique. This is especially useful for treating patients with large burns who have limited donor tissue availability.

UDL Laboratories is part of Mylan Institutional, a platform that provides differentiated pharmaceutical products to institutional customers throughout North America. Mylan Institutional's product offering includes the specialty injectables of Bioniche Pharma with the unit dose capabilities of Mylan's UDL Laboratories. Mylan Institutional's customers include group purchasing organizations, wholesalers, hospitals, surgical and radiology services, home infusion service providers, long-term care facilities, correctional facilities, specialty pharmacies, veterinary clinics and retail outlets.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... 2016 Valeritas Holdings, Inc. (OTCQB: ... public offering (APO). This was accomplished via a reverse ... and a private placement of approximately 5 million shares ... Under the terms of the reverse merger, ... Inc. will trade on the OTC Markets under the ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Ischemic Stroke ...  report to their offering.       ... Global Acute Ischemic Stroke Market and ... into Acute Ischemic Stroke pipeline products, Acute ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... ... for knees, ankles, and elbows. Engineered with athletes in mind, OMNIFORCE offers ... (opposed to ineffective circular knitting, common in the industry) produces premium flat-knit ...
(Date:5/4/2016)... British Columbia – , ... ... Wimmzi , a manufacturer of innovative infant and child products, today ... toys. But their ability to help babies deal with teething pain ... FDA approved, contain no toxic gels, and are BPA-, PVC-, and ...
(Date:5/4/2016)... California (PRWEB) , ... May 04, 2016 , ... With ... Research (AACR) honors the month of May as National Cancer Research Month. According to ... million new diagnoses of cancer with predications of one in four Americans dying as ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Over 40 athletic ... in the state capitol for the annual “Hike to Harrisburg” advocacy day. The ... The Winter Group, PATS lobby Group. The goal for the day was to ...
(Date:5/4/2016)... ... May 04, 2016 , ... International Conference on ... July 25-27, 2016 at Las Vegas. It aims to bring together academicians, scientists, ... and research organizations across the globe; making the conference a perfect platform to ...
Breaking Medicine News(10 mins):